Medical Technology

@xconomy.com 3 years ago

Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

@xconomy.com 4 years ago

DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs

@xconomy.com 4 years ago

California Life Sciences Fueled by Education, Established Companies

@xconomy.com 4 years ago

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

@xconomy.com 5 years ago

Former Zavante Executive Tapped as Abide Therapeutics President

@xconomy.com 5 years ago

Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections

@xconomy.com 5 years ago

With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?

@xconomy.com 5 years ago

Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines